Results 11 to 20 of about 4,313 (158)

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

Frontiers in Pharmacology, 2022
Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Masakiyo Yatomi, Haruka Aoki-Saito, Yasuhiko Koga   +2 more
exaly   +3 more sources

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics [PDF]

Pulmonary Therapy
Introduction Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective.
Eileen O. Dareng, Trung N. Tran, Hannah Urbanski, Ryan Finch, Ulrika Emerath, Yulia Kurdyukova, Maria L. Jison, Lila Bahadori, Andrew Menzies-Gow, Eileen Wang, Elisabeth H. Bel, Luis Perez de Llano, Benjamin Emmanuel, Lynda Olinger   +13 more
doaj   +2 more sources

Benralizumab in bronchiectasis: results from the phase 3 MAHALE study [PDF]

ERJ Open Research
Background Bronchiectasis is a chronic, inflammatory lung disease with distinct endotypes, often defined by inflammatory cells in blood and sputum. We assessed safety and efficacy of benralizumab, an anti-interleukin-5Rα monoclonal antibody, in patients ...
James D. Chalmers, Stefano Aliberti, Lucy Burr, Ulla Møller Weinreich, Miguel Ángel Bergna, Annika Åstrand, Prashanth Basavanna, Ying Fan, Maura Gatti, Calvin N. Ho, Stefan Ivanov, Christopher McCrae, Ana Román, Svitlana Salemio, Maria Jison   +14 more
doaj   +2 more sources

Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study [PDF]

Journal of Asthma and Allergy
Pradeep B Lukka,1 Robert C Penland,1 Ari Brekkan,2 Rami Ayoun Alsoud,2 Sherri So,3 David W Boulton1 1Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA ...
Lukka PB, Penland RC, Brekkan A, Ayoun Alsoud R, So S, Boulton DW   +5 more
doaj   +2 more sources

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings

Фармакоэкономика, 2022
Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe ...
M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin   +3 more
doaj   +1 more source

Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma

Biomolecules, 2023
Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine.
Yuuki Sandhu, Norihiro Harada, Hitoshi Sasano, Sonoko Harada, Shoko Ueda, Tomohito Takeshige, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Sumiko Abe, Tetsutaro Nagaoka, Jun Ito, Asako Chiba, Hisaya Akiba, Ryo Atsuta, Kenji Izuhara, Sachiko Miyake, Kazuhisa Takahashi   +17 more
doaj   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease. [PDF]

Clin Transl Allergy
ABSTRACT Background Aspirin‐exacerbated respiratory disease (AERD), also termed nonsteroidal anti‐inflammatory drug exacerbated respiratory disease (NERD), is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase‐1 inhibitors, frequently resulting in severe, treatment‐refractory airway disease ...
Priessnitz JK, Hagopian A, Patev AJ, Han JK, Lam KK.   +4 more
europepmc   +2 more sources

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source